GLP-1 family
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al. · N Engl J Med · 2023
PMID: 37366315 · DOI: 10.1056/NEJMoa2301972
Summary
Phase 2 randomized, double-blind, placebo-controlled trial of subcutaneous retatrutide (GIP/GLP-1/glucagon agonist) at 1, 4, 8, 12 mg vs placebo over 48 weeks in 338 adults with obesity. Primary endpoint: percent change in body weight.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
Compounds referenced in this study
- View product →GLP-3 RTriple-receptor incretin class agonist studied in metabolic-pathway research.
Guides covering this compound
More GLP-1 family citations
- Once-Weekly Semaglutide in Adults with Overweight or ObesityN Engl J Med · 2021
- Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)Lancet · 2021
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3)JAMA · 2021